The efficacy of CpG oligodinucleotides, in combination with conventional adjuvants, as immunological adjuvants to swine streptococcic septicemia vaccine in piglets in vivo

Zhang, Linghua; Tian, Xiaoli; Zhou, Fengzhen

doi:10.1016/j.intimp.2006.03.009

Cited by 19 publications

(12 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In an immunization model, encapsulation of CpG-ODN with the liposomal adjuvant CL increased IFN-and IgG responses by 15-to 40-fold compared with CpG-ODN alone [31]. These findings provide support the use of stabilized cationic lipids significantly enhance the therapeutic efficacy of CpG-ODN [31,32].…”

Section: Introductionmentioning

confidence: 52%

See 1 more Smart Citation

Enhancement of Immunoprotective Effect of CpG-ODN by Formulation with Polyphosphazenes Against E. coli Septicemia in Neonatal Chickens

Taghavi¹,

Allan²,

Mutwiri³

et al. 2009

CDD

View full text Add to dashboard Cite

Synthetic oligodeoxynucleotides (ODN) containing CpG motifs (CpG-ODN) have been shown to be effective immunoprotective agents and vaccine adjuvants in a variety of bacterial and protozoan diseases in different animal species. The objective of this study was to investigate the immunoprotective effect of formulated CpG-ODN with polyphosphazene, liposome or oil-in-water emulsion against E. coli infections in neonatal chickens. Eighteen-day-old embryonating eggs were inoculated with 50 microg CpG-ODN or formulated CpG-ODN with polyphophazene, liposome or oil-in-water emulsion. Four days after exposure to formulated CpG-ODN or day-1 post-hatch, 1 x 10(4) or 1 x l0(5) cfu of a virulent isolate of E. coli was inoculated by the subcutaneous route in the neck. Clinical signs, pathology, bacterial isolations from the air sacs, and mortality were observed for eight days following challenge with E. coli. The survival rate of birds following E. coli infection was 0% in groups receiving either non-CpG-ODN or saline. In contrast, birds receiving either CpG-ODN or CpG-ODN formulated with polyphosphazene had significantly higher survival of 55% (P<0.0001). The relative risk of mortality was significantly reduced for birds treated with CpG-ODN formulated in PCPP (0.25), in PCEP (0.33), or unformulated CpG-ODN (0.39) in comparison to the group treated with saline (p<0.01). Although formulation of CpG-ODN with liposomes or oil-in-water emulsion did not increase the immunoprotective effect against E. coli infection, no adverse reactions or poor hatchability were observed in embryos. This is the first time that CpG-ODN formulated with polyphosphazene has been demonstrated to have an immunoprotective effect against an extra cellular bacterial infection in neonatal broiler chickens following in ovo delivery.

show abstract

Section: Introductionmentioning

confidence: 52%

“…This adjuvant acts by forming a mobile depot of antigen, which can target immune effectors cells such as, IFN-, Th 1, and IgG [32][33][34]. The depot effect, which results in slow release of Emulsigen®, improves the presentation of antigens, thereby enhancing the immune response [33,35].…”

Section: Introductionmentioning

confidence: 99%

Enhancement of Immunoprotective Effect of CpG-ODN by Formulation with Polyphosphazenes Against E. coli Septicemia in Neonatal Chickens

Taghavi¹,

Allan²,

Mutwiri³

et al. 2009

CDD

View full text Add to dashboard Cite

show abstract

“…Fewer studies have analyzed alum-polarizing effects in swine. Although an IgG2 response is also observed in pigs vaccinated with alum-adjuvanted vaccines, a higher IgG1/IgG2 ratio is observed, suggesting a predominant Th2 immune response [58,59]. In vitro, swine DCs responded to alum with a mixed type1/type2 cytokine profile.…”

Section: Discussionmentioning

confidence: 99%

“…In vitro, swine DCs responded to alum with a mixed type1/type2 cytokine profile. It has been proposed that alum mainly stimulates a Th2 immune response without affecting the Th1 response [59]. Using different immunization protocols, a study showed that type 1 and type 2 components were present in all protocols, and it was the balance between the opposing cytokines that determined the final outcome of the humoral response in vivo [60].…”

Section: Discussionmentioning

confidence: 99%

Porcine Dendritic Cells as an In Vitro Model to Assess the Immunological Behaviour of Streptococcus suis Subunit Vaccine Formulations and the Polarizing Effect of Adjuvants

et al. 2017

View full text Add to dashboard Cite

An in vitro porcine bone marrow-derived dendritic cell (DC) culture was developed as a model for evaluating immune polarization induced by adjuvants when administered with immunogens that may become vaccine candidates if appropriately formulated. The swine pathogen Streptococcus suis was chosen as a prototype to evaluate proposed S. suis vaccine candidates in combination with the adjuvants Poly I:C, Quil A ®, Alhydrogel ®, TiterMax Gold ® and Stimune ®. The toll-like receptor ligand Poly I:C and the saponin Quil A ® polarized swine DC cytokines towards a type 1 phenotype, with preferential production of IL-12 and TNF-α. The water-in-oil adjuvants TiterMax Gold ® and Stimune ® favoured a type 2 profile as suggested by a marked IL-6 release. In contrast, Alhydrogel ® induced a type 1/type 2 mixed cytokine profile. The antigen type differently modified the magnitude of the adjuvant effect, but overall polarization was preserved. This is the first comparative report on swine DC immune activation by different adjuvants. Although further swine immunization studies would be required to better characterize the induced responses, the herein proposed in vitro model is a promising approach that helps assessing behaviour of the vaccine formulation rapidly at the pre-screening stage and will certainly reduce numbers of animals used while advancing vaccinology science.

show abstract

“…Alhydrogel ™ commonly known as aluminum hydroxide, binds antigen and incorporates into an insoluble, gel-like precipitate and is believed to continually stimulate the immune system by functioning as an antigen depot [22]. The use of CpG and Alhydrogel ™ as a combination adjuvant is reported to enhance immune responses significantly greater than the use of either adjuvant alone [22–24] and was also evaluated.…”

Section: 0 Introductionmentioning

confidence: 99%

Evaluation of formalin inactivated V3526 virus with adjuvant as a next generation vaccine candidate for Venezuelan equine encephalitis virus

Martin¹,

Bakken

Lind

et al. 2010

Vaccine

View full text Add to dashboard Cite

V3526, a genetically modified strain of Venezuelan equine encephalitis virus (VEEV), was formalin inactivated for evaluation as a next generation vaccine candidate for VEEV. In this study, we tested formalin-inactivated V3526 (fV3526) with and without adjuvant for immunogenicity and efficacy in BALB/c mice and results were compared to the existing inactivated VEEV vaccine, C84. Mice were vaccinated intramuscularly (IM) or subcutaneously (SC) with fV3526 formulations and challenged with VEEV IAB Trinidad donkey (VEEV TrD) strain by SC or aerosol exposure. Efficacy following SC or aerosol challenge was not significantly different between the fV3526 formulations or compared to C84 despite C84 being administered in more doses and higher concentration of viral protein per dose. These data support further evaluation of fV3526 formulations as a next generation VEEV vaccine.

show abstract

The efficacy of CpG oligodinucleotides, in combination with conventional adjuvants, as immunological adjuvants to swine streptococcic septicemia vaccine in piglets in vivo

Cited by 19 publications

References 43 publications

Enhancement of Immunoprotective Effect of CpG-ODN by Formulation with Polyphosphazenes Against E. coli Septicemia in Neonatal Chickens

Enhancement of Immunoprotective Effect of CpG-ODN by Formulation with Polyphosphazenes Against E. coli Septicemia in Neonatal Chickens

Porcine Dendritic Cells as an In Vitro Model to Assess the Immunological Behaviour of Streptococcus suis Subunit Vaccine Formulations and the Polarizing Effect of Adjuvants

Evaluation of formalin inactivated V3526 virus with adjuvant as a next generation vaccine candidate for Venezuelan equine encephalitis virus

Contact Info

Product

Resources

About